指南与共识重症综合管理与镇静镇痛呼吸衰竭与机械通气消化、代谢与肾脏急症

癌症合并COVID-19患者的血栓栓塞性疾病:危险因素、预防与实用血栓预防建议——最新进展

Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations-State-of-the-Art.
指南 / 共识 · Anticancer Res · 2022-01-01
一句话结论现有数据不支持癌症合并COVID-19患者存在叠加血栓风险;应按现有推荐用成熟风险评估模型评估,优先使用低分子肝素进行血栓预防。

本文综述癌症与COVID-19各自通过多层面机制增加静脉血栓事件,但两者合并时是否叠加血栓风险尚不明确。当前数据不支持癌症合并COVID-19患者存在叠加血栓风险。癌症患者接受重症监护的机会较少,而重症监护本身与高血栓风险相关。基于现有证据,癌症合并COVID-19患者应使用针对内科疾病患者的成熟风险评估模型进行评估,并按现有推荐接受血栓预防,优先选择低分子肝素。目前尚无针对特征明确人群的前瞻性试验。

要点

  • 当前数据不支持癌症合并COVID-19患者存在叠加血栓风险。
  • 癌症合并COVID-19患者应使用针对内科疾病患者的成熟风险评估模型进行评估,并按现有推荐接受血栓预防,优先选择低分子肝素。
  • 活动性癌症住院患者和接受抗癌治疗的高危门诊癌症患者推荐进行血栓预防。
  • COVID-19住院患者目前推荐普遍性血栓预防,使用高预防剂量低分子肝素,或对特定患者使用治疗剂量。
  • 血栓形成高风险或疾病恶化高风险的COVID-19门诊患者推荐预防性抗凝;癌症患者接受重症监护的机会较少,而该环境与高血栓风险相关。

适用人群与场景

  • 活动性癌症住院患者;接受抗癌治疗的高危门诊癌症患者。
  • COVID-19住院患者;血栓形成高风险或疾病恶化高风险的COVID-19门诊患者。
  • 癌症合并COVID-19患者,应使用针对内科疾病患者的成熟风险评估模型进行评估。

处置流程与药物剂量

  • 活动性癌症住院患者和接受抗癌治疗的高危门诊癌症患者推荐进行血栓预防。
  • COVID-19住院患者目前推荐普遍性血栓预防,使用高预防剂量低分子肝素,或对特定患者使用治疗剂量。
  • 血栓形成高风险或疾病恶化高风险的COVID-19门诊患者推荐预防性抗凝。
  • 癌症合并COVID-19患者按现有推荐接受血栓预防,优先使用低分子肝素。

研究设计与关键结果

  • 综述总结并批判性讨论了癌症合并COVID-19患者血栓事件的流行病学、血栓风险评估及该亚组患者血栓预防推荐。
  • 当前数据不支持癌症合并COVID-19患者存在叠加血栓风险。
  • 癌症患者接受重症监护的机会较少,而重症监护环境与高血栓风险相关。
  • 目前尚无针对特征明确人群的前瞻性试验。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:目前尚无针对特征明确人群的前瞻性试验。

对床旁实践的改变

  • 癌症合并COVID-19患者应使用针对内科疾病患者的成熟风险评估模型进行评估,并按现有推荐接受血栓预防,优先使用低分子肝素。
  • 活动性癌症住院患者和接受抗癌治疗的高危门诊癌症患者推荐进行血栓预防。
  • COVID-19住院患者目前推荐普遍性血栓预防,使用高预防剂量低分子肝素,或对特定患者使用治疗剂量;血栓形成高风险或疾病恶化高风险的COVID-19门诊患者推荐预防性抗凝。

指南或共识出处

  • Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations-State-of-the-Art(Anticancer Res)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Cancer and COVID-19 are both well-established risk factors predisposing to thrombosis. Both disease entities are correlated with increased incidence of venous thrombotic events through multifaceted pathogenic mechanisms involving the interaction of cancer cells or SARS-CoV2 on the one hand and the coagulation system and endothelial cells on the other hand. Thromboprophylaxis is recommended for hospitalized patients with active cancer and high-risk outpatients with cancer receiving anticancer treatment. Universal thromboprophylaxis with a high prophylactic dose of low molecular weight heparins (LMWH) or therapeutic dose in select patients, is currentlyindicated for hospitalized patients with COVID-19. Also, prophylactic anticoagulation is recommended for outpatients with COVID-19 at high risk for thrombosis or disease worsening. However, whether there is an additive risk of thrombosis when a patient with cancer is infected with SARS-CoV2 remains unclear In the current review, we summarize and critically discuss the literature regarding the epidemiology of thrombotic events in patients with cancer and concomitant COVID-19, the thrombotic risk assessment, and the recommendations on thromboprophylaxis for this subgroup of patients. Current data do not support an additive thrombotic risk for patients with cancer and COVID-19. Of note, patients with cancer have less access to intensive care unit care, a setting associated with high thrombotic risk. Based on current evidence, patients with cancer and COVID-19 should be assessed with well-established risk assessment models for medically ill patients and receive thromboprophylaxis, preferentially with LMWH, according to existing recommendations. Prospective trials on well-characterized populations do not exist.

来源:Anticancer Res,查看原文。版权归原作者所有。

参考来源

  1. Dimakakos E, Gomatou G, Catalano M, et al. Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations-State-of-the-Art. Anticancer Res. 2022. PMID: 35790272. doi:10.21873/anticanres.15815

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。